Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...

Lilly’s offering is expected to surpass Novo’s Wegovy in the space ... For one, Lilly in early December shared the results of a head-to-head trial pitting Zepbound against Wegovy, in which ...

According to leading data and analytics company GlobalData, Eli Lilly’s Zepbound (tirzepatide) is poised to surpass Novo Nordisk ... Recent head-to-head trial results demonstrated the superior ...

The phase 3 SURPASS-4 trial published in 2021 established that tirzepatide lowers blood sugar and supports weight loss better than insulin glargine (a long-acting insulin) for type 2 diabetes (T2D).

Market research firm GlobalData noted on the 2nd that Eli Lilly's obesity drug Zeb Bound will quickly surpass Novo ... Zeb Bound (ingredient name tirzepatide) is a latecomer that received approval ...

Credit: Ciara Kimsey / Shutterstock. Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment ...

Recent head-to-head trial results demonstrated the superior ... a more cost-effective option for patients, it may surpass Novo Nordisk in the obesity treatment market. Despite the recent launch of ...

The company recently released results from the SURMOUNT-5 trial, which demonstrated that tirzepatide, marketed as Mounjaro for ... a measure of average blood sugar over three months. In the Phase 3 ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...